<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-8453</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Saúde Ocupacional online]]></journal-title>
<abbrev-journal-title><![CDATA[RPSO]]></abbrev-journal-title>
<issn>2183-8453</issn>
<publisher>
<publisher-name><![CDATA[Ajeogene Serviços Médicos Lda]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-84532021000200013</article-id>
<article-id pub-id-type="doi">10.31252/rpsp.27.11.2021</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[RELAÇÃO ENTRE IDADE E IMUNIDADE PARA A COVID-19 EM PROFISSIONAIS DE SAÚDE VACINADOS]]></article-title>
<article-title xml:lang="en"><![CDATA[RELATIONSHIP BETWEEN AGE AND IMMUNITY FOR COVID-19 IN VACCINED HEALTHCARE PROFESSIONALS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vilas Boas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sampaio]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barbosa]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidade de Coimbra Universidade do Minho ]]></institution>
<addr-line><![CDATA[Viana do Castelo ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidade de Coimbra desde Faculdade de Medicina da Universidade do Porto desde ]]></institution>
<addr-line><![CDATA[Viana do Castelo ]]></addr-line>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidade de Coimbra Universidade de Miguel Hernández de Elche - Alicante (Espanha) ]]></institution>
<addr-line><![CDATA[Vila Nova de Famalicão ]]></addr-line>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidade do Porto  ]]></institution>
<addr-line><![CDATA[Viana do Castelo ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>12</volume>
<fpage>13</fpage>
<lpage>21</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-84532021000200013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-84532021000200013&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-84532021000200013&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO  Introdução O início da vacinação contra a Covid-19 coloca algumas questões sobre a eficácia, segurança, durabilidade da proteção e necessidade de doses de reforço. O doseamento dos anticorpos IgG anti-spike pode ajudar a responder a estas questões, assim como a diminuir o contágio entre Profissionais de Saúde e doentes, assegurando a capacidade de resposta do Serviço Nacional de Saúde.  Objetivos Avaliar o título de anticorpos IgG anti-spike em profissionais de saúde vacinados, aos três e seis meses após a vacinação completa e como variam de acordo com a idade.  Metodologia Foi realizado o doseamento dos anticorpos IgG anti-spike contra o SARS-CoV2 num grupo de 923 profissionais de Saúde de uma Unidade Local de Saúde aos três e seis meses após a vacinação com a vacina COMIRNATY®. O teste serológico usado foi o imunoensaio quimioluminescente totalmente automatizado (Abbott). Procedeu-se à recolha de dados epidemiológicos, como a Idade, Sexo e Categoria Profissional e determinou-se se existiria relação entre os títulos de anticorpos e a idade.  Resultados Dos 923 participantes, a maioria eram mulheres (81.4%) e a idade média foi de 45.51 anos. Obteve-se uma média de 6452.61 AU/mL aos três meses e 2011.17AU/mL aos seis meses nos títulos de anticorpos, com uma queda de 68.84% dos três para os seis meses. Dos resultados obtidos pode-se referir que os valores dos anticorpos variam com a idade: quanto maior a idade, menor o número de anticorpos produzidos, sendo que dos três para os seis meses essa associação é mais forte, ou seja, as pessoas mais idosas produzem menos anticorpos e perdem-nos intensamente ao longo do tempo.  Discussão/Conclusão O doseamento de anticorpos IgG anti-spike não pode ser visto como medida única de eficácia da vacina, existe também um componente importante da imunidade humoral que ainda não sabemos ao certo a verdadeira importância. O doseamento de anticorpos pode vir a fornecer informação relevante sobre a eficácia, a necessidade de reforço vacinal, identificação de grupos de risco e contribuindo para prevenção da doença nos Profissionais de Saúde. Este estudo permite identificar que a maioria das pessoas respondeu bem à vacinação, mas que os anticorpos caiem bruscamente dos três para os seis meses. Permite ainda estabelecer uma relação, ainda que ténue, entre a idade e o título de anticorpos, reforçando a ideia de reforçar a vacinação nas pessoas mais velhas.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction The initiation of vaccination against Covid-19 raises some questions about the effectiveness, safety, durability of protection and the need for booster doses. The measurement of anti-spike IgG antibodies can help to answer these questions, as well as to reduce the contagion between Health Professionals and patients, ensuring the responsiveness of the National Health Service.  Objectives Assess the anti-spike IgG antibody titles in vaccinated healthcare professionals at three and six months after full vaccination and how they vary with age.  Methodology Anti-spike IgG antibodies against SARS-CoV2 were measured in a group of 923 health professionals from a Local Health Unit at three and six months after vaccination with the COMIRNATY® vaccine. The serological test used was the fully automated chemiluminescent immunoassay (Abbott). Epidemiological data was collected, such as Age, Gender and Professional Category, and it was determined whether there was a relationship between antibody titles and age.  Results Of the 923 participants, the majority were women (81.4%), and the mean age was 45.51 years. Antibody titles averaged 6452.61 AU/mL at three months and 2011.17AU/mL at six months, with a drop of 68.84% from three to six months. From the results obtained, it can be noted that antibody values vary with age: the older the age, the lower the number of antibodies produced, and from three to six months this association is stronger, that is, older people produce fewer antibodies, and they lose them intensely over time.  Discussion/Conclusion The measurement of IgG anti-spike antibodies cannot be seen as a unique measure of vaccine efficacy, there is also an important component of humoral immunity that we still do not know for sure the true importance. Antibody dosing may provide relevant information about efficacy, the need for vaccine booster, identification of risk groups and contributing to disease prevention in Health Professionals. This study allows us to identify that most people responded well to vaccination, but that the antibodies drop sharply from three to six months. It also makes it possible to establish a relationship, albeit tenuous, between age and antibody titles, reinforcing the idea of boosting vaccination in older people.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Covid-19]]></kwd>
<kwd lng="pt"><![CDATA[Vacina]]></kwd>
<kwd lng="pt"><![CDATA[Imunidade]]></kwd>
<kwd lng="pt"><![CDATA[Anticorpos]]></kwd>
<kwd lng="pt"><![CDATA[Idade]]></kwd>
<kwd lng="pt"><![CDATA[Saúde Ocupacional]]></kwd>
<kwd lng="en"><![CDATA[Covid-19]]></kwd>
<kwd lng="en"><![CDATA[Vaccine]]></kwd>
<kwd lng="en"><![CDATA[Immunity]]></kwd>
<kwd lng="en"><![CDATA[Antibodies]]></kwd>
<kwd lng="en"><![CDATA[Age]]></kwd>
<kwd lng="en"><![CDATA[Occupational Health]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Coronavírus [Internet]</collab>
<source><![CDATA[Who.int]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Akondy]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insights into human CD8+ T-cell memory using the yellow fever and smallpox vaccines]]></article-title>
<source><![CDATA[Immunology and Cell Biology]]></source>
<year>2011</year>
<volume>89</volume>
<page-range>340-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>[Internet]</collab>
<source><![CDATA[Fda.gov]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Zahn]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wegmann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Loos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chandrashekar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>586</volume>
<numero>7830</numero>
<issue>7830</issue>
<page-range>583-8</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMahan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mercado]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Loos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tostanoski]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chandrashekar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlates of protection against SARS-CoV-2 in rhesus macaques]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>590</volume>
<numero>7847</numero>
<issue>7847</issue>
<page-range>630-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulligan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lyke]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kitchin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Absalon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gurtman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lockhart]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2020</year>
<volume>586</volume>
<numero>7830</numero>
<issue>7830</issue>
<page-range>589-93</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>[Internet]</collab>
<source><![CDATA[Biorxiv.org]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives]]></article-title>
<source><![CDATA[Pharmaceutical Research]]></source>
<year>2021</year>
<volume>38</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>473-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khurana]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Allawadhi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Khurana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Allwadhi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Weiskirchen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Banothu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of nanotechnology behind the success of mRNA vaccines for COVID-19]]></article-title>
<source><![CDATA[Nano Today]]></source>
<year>2021</year>
<volume>38</volume>
<page-range>101142</page-range><publisher-name><![CDATA[Elsevier B.V]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>PMC E. Europe PMC [Internet]</collab>
<source><![CDATA[Europepmc.org]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hodgson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mansatta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mallett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Emary]]></surname>
<given-names><![CDATA[KRW]]></given-names>
</name>
<name>
<surname><![CDATA[Pollard]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2]]></article-title>
<source><![CDATA[The Lancet Infectious Diseases]]></source>
<year>2021</year>
<volume>21</volume>
<page-range>e26-35</page-range><publisher-name><![CDATA[Lancet Publishing Group]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>Direção Geral da Saúde</collab>
<source><![CDATA[Campanha de Vacinação Contra a COVID-19, Norma nº 002/2021 de 30/01/2021 atualizada a 04/05/2021]]></source>
<year>2021</year>
<page-range>1-2</page-range><publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Direção Geral da Saúde]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Review of: &#8220;Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial.&#8221; Qeios [Internet]]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wajnberg]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Amanat]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Firpo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bailey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Robust neutralizing antibodies to SARS-CoV-2 infection persist for months]]></article-title>
<source><![CDATA[Science]]></source>
<year>2020</year>
<volume>370</volume>
<numero>6521</numero>
<issue>6521</issue>
<page-range>1227-30</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[GeurtsvanKessel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Okba]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Igloi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Bogers]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Embregts]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Laksono]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment]]></article-title>
<source><![CDATA[Nature Communications]]></source>
<year>2020</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eyre]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lumley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cox]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Justice]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status]]></article-title>
<source><![CDATA[Clinical Microbiology and Infection]]></source>
<year>2021</year>
<volume>27</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1516.e7-1516.e14</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>Summary of the Public Assessment Report for COVID-19 Vaccine Pfizer/BioNTech [Internet]</collab>
<source><![CDATA[GOV.UK]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salvagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[di Piazza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pighi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[de Nitto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bragantini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-sars-cov-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination]]></article-title>
<source><![CDATA[Diagnostics]]></source>
<year>2021</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dörschug]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Frickmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Schwanbeck]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mese]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays]]></article-title>
<source><![CDATA[Diagnostics]]></source>
<year>2021</year>
<volume>11</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>426</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Monin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Laing]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz-Ruiz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McKenzie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Barrio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alaguthurai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study]]></article-title>
<source><![CDATA[The Lancet Oncology]]></source>
<year>2021</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>765-78</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
